Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
2026 · 3rd Quarter (July 1 - Sep 30)
NRX PHARMACEUTICALS INC (FORMERLY KNOWN AS NEURORX)
Filed by TWENTY-FIRST CENTURY GROUP, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $24,000.00
- Expenses
- Not reported
- Registrant
- TWENTY-FIRST CENTURY GROUP, INC.
- Filing UUID
- f1543961-b50a-4aa5-aa0b-3e9826afe5bf
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD within HR 8646, Fiscal Year 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Bill; ALS research and treatment related to HR 9495, Fiscal Year 2027 Defense Appropriations Bill.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.